The Control of Hypertension in Pregnancy Study (CHIPS) is an open, multicentre, international, randomised controlled trial with an intention-to -treat analysis.
The study is pragmatic: it is being undertaken to reflect real clinical practice rather than the very tightly controlled circumstances of explanatory trials. The pragmatic approach is important in this trial, where the interventions are policies of ‘less tight’ and ‘tight’ control, and it is not possible to blind clinicians or patients to the dBP goals of each treatment group.
Eligible women are being randomised centrally to either ‘less tight’ control (aiming for dBP of 100 mmHg) or ‘tight’ control (aiming for dBP of 85 mmHg) of their hypertension.
The primary outcome is outcome for the infants, irrespective of the way the policies are administered. The secondary outcome is outcome for the mother.
In the November 2013 issue of the CHIPS newsletter you will find information about the following:
CHIPS Data Campaign and Database Closure—FINAL CALL FOR OUTSTANDING QUERIES!
Final International Collaborators’ Meeting February 20, 2014—Last Request for Registration Responses!
Acknowledgement lists for the main CHIPS publication
Wishes for a Happy Holiday Season!